Article Details

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma - OncLive

Retrieved on: 2024-04-09 17:12:49

Tags for this article:

Click the tags to see associated articles and topics

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma - OncLive. View article details on hiswai:

Excerpt

Jun Guo, MD, PhD. The National Medical Products Administration of China has approved toripalimab combined with axitinib (Inlyta) ...

Article found on: www.onclive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo